Conventional chemotherapeutics nonselectively kill all rapidly dividing cells, which produces numerous side effects. To address this challenge, we report the discovery of functional polyesters that are capable of delivering siRNA drugs selectively to lung cancer cells and not to normal lung cells. Selective polyplex nanoparticles (NPs) were identified by high-throughput library screening on a unique pair of matched cancer/normal cell lines obtained from a single patient. Selective NPs promoted rapid endocytosis into HCC4017 cancer cells, but were arrested at the membrane of HBEC30-KT normal cells during the initial transfection period. When injected into tumor xenografts in mice, cancer-selective NPs were retained in tumors for over 1 wk, whereas nonselective NPs were cleared within hours. This translated to improved siRNA-mediated cancer cell apoptosis and significant suppression of tumor growth. Selective NPs were also able to mediate gene silencing in xenograft and orthotopic tumors via i.v. injection or aerosol inhalation, respectively. Importantly, this work highlights that different cells respond differentially to the same drug carrier, an important factor that should be considered in the design and evaluation of all NP carriers. Because no targeting ligands are required, these functional polyester NPs provide an exciting alternative approach for selective drug delivery to tumor cells that may improve efficacy and reduce adverse side effects of cancer therapies.
functional polyesters | siRNA | cancer | drug delivery | nanoparticles L ung cancer is the leading cause of new cancer cases and cancer-related mortality worldwide (1) . Most anticancer drugs indiscriminately kill all dividing cells, manifesting in hair loss, fatigue, infection, and other problems (2) (3) (4) . Extensive efforts have been made to design new drugs that selectively target precise pathways driving the development of specific cancers, but many attractive cancer targets remain undruggable (5, 6 ). Short interfering RNA (siRNA)-based therapies are a promising alternative approach because they can theoretically silence expression of any oncogene (5, 7, 8) . However, siRNA sequences must be carefully designed to minimize off-target effects and toxicity, especially toward healthy cells (9, 10) . Improving selectivity to cancer cells would have a transformative impact on the future of both chemotherapeutic small molecule drugs and RNA-based cancer treatment (3, 4, 11, 12) . A critical unmet challenge therefore is to design delivery carriers that are specific to cancer cells to improve efficacy and reduce off-target effects to normal cells (4, 10) .
Targeted drug delivery traditionally involves modifying the surface of nanoparticles with tumor-specific targeting motifs such as antibodies (13) , aptamers (14) , transferrin protein (15), short peptides (16) , or ligands (17) . However, the specific interaction between these motifs and their targets can be reduced in vivo due to conformational change of proteins (18) , variable expression of targets on cell surfaces (12) , and the masking of ligand display by adsorption of serum proteins on the delivery vehicle (19) . As an alternative strategy, we hypothesized that the physicochemical properties of the polymeric carriers alone may enable selective delivery of polymer-siRNA polyplex nanoparticles (NPs) to cancer cells but not normal cells. We show that the physiochemical properties of materials alone can endow selective delivery to specific cells, suggesting a new way to avoid drug side effects, and illuminating the unappreciated reality that NP carriers exhibit cell type-dependent delivery.
A large number of materials have been developed that can effectively deliver nucleic acids, but these systems have not been shown to provide selectivity between cell types (8) . We focused on polyesters because they have been safely used in numerous Food and Drug Administration-approved products (20) . Nevertheless, scalable synthesis and modification of functional polyesters is an ongoing challenge (21) (22) (23) (24) . We recently developed a scalable method to yield functional polyesters based on the polycondensation of trimethylolpropane allyl ether and diacyl chlorides with tunable molecular weight (MW) (22) . This methodology allows for construction of chemically diverse polyesters because thiol-ene click reactions (25) permit the facile modification of chemical functionality and physical properties. Herein, we have applied this synthetic method to design a polymer library containing 840 functional polyesters with varying MW and chemical identities to maximize potential variance in physicochemical properties to meet siRNA delivery requirements and provide enough structural diversity to discover cancer cell-specific NPs.
To identify cancer cell-specific NPs, we used a matched tumor/normal lung cell line pair (HCC4017/HBEC30-KT), derived
Significance
Ideal cancer therapeutics accurately hit tumors and avoid side effects on healthy cells. We used a patient-derived pair of matched cancer/normal cell lines to discover selective nanoparticles that could deliver a cytotoxic siRNA to kill cancer cells and not normal cells. The finding that cells respond differently to the same nanoparticle has profound implications for gene therapy because cell-type specificity of drug carriers in vivo could alter clinical patient outcomes. Our data suggest that selectivity is an underappreciated reality that should be carefully considered when evaluating drug carriers. The combination of both well-defined molecular targets and nanoparticle delivery to targeted cells is likely required to improve cancer drug accuracy in the clinic.
from a single female lung cancer patient (26) . We report the discovery of selective polyester siRNA polyplex NPs that provide cancer specific therapy (Fig. 1A ) in vitro and in vivo. We delivered siRNA targeting ubiquitin B (siUBB) (27, 28) , which causes cell death in all cell types to evaluate the delivery selectivity to HCC4017 tumor cells over HBEC30-KT normal cells. NPs were identified that showed selective cellular uptake to cancer cells over normal cells followed by reduced transport to lysosomes. Cancer cell growth was also selectively suppressed in colony formation assays. In mice, selective NPs exhibited extended retention in tumor tissues and consequently increased siUBB-mediated apoptosis. Selectivity directly translated to suppression of tumor growth as a therapeutic outcome. The translational potential of selective NPs was further validated by siRNA-mediated knockdown in xenograft and orthotopic lung tumors. Because the selectivity of the delivery vehicles relies only on their physicochemical properties, this eliminated the need to attach additional cell-specific targeting motifs. Therefore, these results provide a unique strategy to suppress the side effects of small RNAs to healthy cells/tissues and improve therapeutic efficacy. 
Results

A Scalable Method Enabled Synthesis of Polyesters with Diverse Physiochemical Properties to Facilitate Efficacious siRNA Delivery to
Cancer Cells. To evaluate the hypothesis that functional polyplexes might enable selective siRNA delivery, a large library of biocompatible polymers with tunable functionality was required.
In this paper, we built upon a scalable synthetic strategy (22) to prepare a combinatorial library of functional polyesters for selective siRNA delivery. To diversify the physicochemical properties of the polyesters, 16 amino thiols were synthesized via aminolysis of γ-thiobutyrolactone (SI Appendix, Scheme S1 and Polymeric carriers must overcome a series of extracellular and intracellular barriers to enable siRNAs to be active inside of tumor cells (7) . To verify that this class of functional polyesters can deliver siRNA in vitro, a preliminary 360-member polyester library was first screened in HeLa cells that stably expressed luciferase (HeLaLuc) (SI Appendix, Figs. S3-S5). Initially, the polyesters were modified by only the amino thiols to examine the effect of cationic groups and confirm that this class of materials is capable of silencing luciferase while maintaining low toxicity. Polyesters modified with A3, A5, and A13 were particularly effective, where the silencing depended on the modification degree (SI Appendix, Fig.  S3 ). Furthermore, lower MW polyesters (M w = 4,200 or 8,300) were more effective than higher MW polymers (M w =16,800). This is consistent with previous reports that examined the effect of poly (β-amino ester) MW on delivery, suggesting that higher MW is optimal for plasmid DNA delivery, whereas lower MW is optimal for the shorter, more rigid siRNA (40) (41) (42) (43) .
Focusing on the polyesters with lower MWs, we next examined the effect of hydrophobic side chains to enhance the stability of polyplex NPs (33) (SI Appendix, Fig. S5 ). A second functional polyester library of 520 comodified polyesters was synthesized. Polymers are named by the starting MW, followed by the amino thiol and the alkyl thiol feed ratio (e.g., PE4K-A1-0.2C6). Structure-activity analysis of a heat map showing luciferase silencing indicated that the area with lower MW (PE4K) and longer alkyl thiols (C12SH) and the area with higher MW (PE8K) and shorter alkyl thiols (C6SH and C10SH) were the most active. This suggests that, in addition to optimal cationic nature and pK a , effective siRNA delivery requires a balance between the polymer MW and hydrophobicity that relates to physical chain entanglement and intermolecular forces (23, 35, 39, 44) . The top-performing polymers show superior delivery activity over the commercial benchmark RNAiMax according to dose-response curves (SI Appendix, Fig. S4 ). Fig. 2 . Delivery of siUBB in functional polyester NPs was evaluated in patient-derived NSCLC lines to establish selectivity. (A) Polymer-siUBB NPs exhibited differential delivery efficacy to HCC4017 and HBEC30-KT cells. NPs were prepared at a weight ratio of 30:1 (polymer:siUBB) in citrate buffer (10 mM, pH 4.2). Cells were treated with siUBB NPs (34.2 nM siUBB) for 6 h followed by a 3-d incubation. Cell viability was quantified to compare treatments. Data are expressed as fold-increase in delivery selectivity toward cancer cells over normal cells. The full data set for each cell line appears in SI Appendix, Table S1 . (B) Activity was validated and compared with a commercial control reagent (RNAiMax). Cancer-selective polymers (modification with A17 and C6SH) and control nonselective polymers (modified with A6 and C6SH) show consistent batch-to-batch delivery activity and selectivity in validation repeat assays (mean ± SD, n = 3). Statistical significance was determined using a two-tailed Student's t test (***, P ≤ 0.001; ns, P > 0.05). (C) Selective siUBB NPs (PE8K-A17-0.2C6 siUBB polyplex NPs) inhibited the colony formation of HCC4017 cells (Left), whereas nonselective siUBB NPs (PE8K-A6-0.2C6 siUBB polyplex NPs) did not (Right). (D) Survival fraction curves show that the colony formation of HCC4017 tumor cells is completely inhibited by selective siUBB NPs at 17.1 nM, whereas >75% of normal HBEC30-KT cells survive when treated with this dose (mean ± SD, n = 3). (E) Selective siUBB NPs were able to kill the majority of an increased panel of patient-derived NSCLC cell lines (mean ± SD, n = 3).
Lung Cancer-Selective Polyplex NPs Were Discovered Through Utilization of a Single Patient-Derived Cancer/Normal Cell Line Pair. To investigate the potential of functional polyesters to be cancer specific, we delivered a pan-toxic siRNA targeting UBB (27, 28) to lung cancer and normal cells derived from single patient to discover cancer cell-selective NPs that show more efficacious siUBB delivery to tumor cells over matched normal cells ( Fig. 2A and SI Appendix, Table S1 ). Treatment with free siUBB or NPs containing control siRNA (siCtrl) showed >90% cell viability for both cell lines under these delivery conditions. A number of functional polyester NPs enabled effective siUBB delivery to both cancer and normal cells (SI Appendix, Table S1 ). To identify the polyplexes that promoted siRNA delivery to cancer cells over normal cells, the difference in the decrease of cell viability (HBEC30-KT viability -HCC4017 viability) was plotted ( Fig. 2A) . This allowed identification of >100 cancer-selective polymers. Notably, A17-0.2C6 modified polymers enabled a 14-fold preferential cell killing to tumor cells. To verify that delivery activity and selectivity was reproducible, we resynthesized all key polymers in larger scale and compared them directly to a well-known transfection reagent (Fig. 2B) . We found that functional polyester-mediated selectivity was consistent. In contrast, RNAiMax showed nearly identical delivery to both tumor and normal cells (80% cell death in both lines at 34.2 nM siUBB). As additional controls, PE8K-A17-0.2C6 siCtrl and PE8K-A6 siUBB NPs did not cause appreciable death in either cell line.
We next examined whether PE8K-A17-0.2C6 siUBB polyplex NPs (hereafter denoted as "selective siUBB NPs") (SI Appendix, Fig. S6 ) could inhibit growth of tumor colonies by conducting a colony formation assay (Fig. 2C) . Selective siUBB NPs could completely abolish colony formation at doses as low as 17.1 nM siUBB. As a control, PE8K-A6-0.2C6 siUBB polyplex NPs (denoted as "nonselective siUBB NPs") show >75% survival fraction at the same dose. Interestingly, these two series of NPs possess nearly identical size, surface charge, and siUBB binding (SI Appendix, Fig. S7 ), but different delivery capability to tumor cells (Fig. 2 A-C) . Particular side-chain functionalities may regulate endocytosis and control siRNA intracellular release. The selectivity of selective siUBB NPs to colony formation of cancer versus normal cells is compared in Fig. 2D . The survival fraction of HBEC30-KT (by cell counting) was more than 70% after treatment with 17.1 nM selective siUBB NPs, whereas no HCC4017 tumor clones formed at this dose (see consistency of cell and clone counting in SI Appendix, Fig. S8 ).
To further examine the efficacy of selective siUBB NPs, we extended the screen to a panel of 24 non-small-cell lung cancer (NSCLC) cell lines derived from The University of Texas Southwestern Medical Center (UTSW) patients over the years (Fig. 2E) . Selective siUBB NPs can transfect most of the HCC NSCLC cell lines from our clinic, but not all lines are equally sensitive. We found that even cognate cells respond differently to the same polymer NP, implying that cellular differences should be carefully considered when evaluating any NP-mediated gene therapy. Moreover, we examined an additional 15 cell lines, representative of prostate, breast, liver, colorectal, head and neck, melanoma, ovarian, and pancreatic cancer. Similar to the NSCLC results, selective NPs were effective in most lines and displayed a unique differential delivery capability (SI Appendix, Fig. S9 ). To understand this effect further, we investigated the mechanism of selectivity and evaluated the ability of selective NPs to preferentially deliver siRNA to cancer cells in vitro and in vivo.
Differential Cellular Uptake and Intracellular Dynamics Contributed to Selective Delivery to Cancer over Normal Cells. One key to this study was that combinatorial modification of polyesters with various functional thiols provided the opportunity to diversify the physicochemical properties to overcome a series of delivery barriers. This has been shown to be difficult to realize through rational design of a single polymer (7, 8, 45 ). Overall, 137 polymers (29% of the library) exhibited preferential delivery to cancer cells (Fig. 2A) . However, a large number of polymers also exhibited strong delivery to normal cells (SI Appendix, Table S1 ). Among the 137 selective polymers, the emergence of cysteamine (A17) suggests that this functional group may promote internalization through specialized pathways that reduce trafficking to lysosomes, thereby enhancing siRNA release inside of cancer cells (33, 42, (46) (47) (48) (49) (50) (51) . Previous reports on cysteaminefunctionalized dendrimers (48) and the cell-penetrating peptide Pep-1 (49-51) that contain terminal cysteamine groups suggest that membrane binding and uptake is dependent on this functional group. Overall, the physical properties of the polymers clearly play a role in defining intracellular uptake and siRNA delivery efficacy, as polyplexes with high binding, small size, and positive surface charge were the most likely to be efficacious (SI Appendix, Fig. S10 ). However, the data also show that selectivity toward different cells is dependent on the chemistry of the NPs and not on the size, binding, or charge (SI Appendix, Fig. S7 ). We therefore speculate that cysteamine, or the resulting physical properties provided by this modification, could play an active role in cell membrane binding, and subsequent endocytosis due to differences in protein or lipid expression on cell surfaces.
To investigate the delivery mechanism, we tracked cellular uptake of selective NPs containing Cy5.5-labeled siRNA to cancer and normal cell lines using confocal microscopy ( Fig. 3) . After 30 min, selective NPs were observed on the cell membrane of both cell lines, visualized by a ring-like Cy5.5-siRNA signal on the cell surface. After 1 h, the fate differentiated between the two cell lines. Within this initial hour, selective Cy5.5-siRNA NPs internalized into HCC4017 cancer cells. In contrast, selective NPs were arrested on the cell membrane of HBEC30-KT normal cells throughout the duration of the incubation time (6 h) (Fig. 3A) . Cellular uptake studies with various endocytosis inhibitors show that internalization of selective NPs to HCC4017 is dominated by the clathrin-dependent pathway (Fig. 3B) . With longer incubation time (24-72 h), some selective NPs are internalized into HBEC30-KT and they completely colocalize with lysosomes ( Fig. 3C and SI Appendix, Fig. S11 ). In contrast, a large amount of siRNA remains outside of lysosomes up to 72 h in HCC4017 cells. The presence of this free siRNA may explain why the silencing of targeted mRNA in the cytoplasm is more effective in HCC4017. Plotting of siRNA (red) versus lysosomes (green) illustrates this differential behavior, confirmed by calculation of Pearson's coefficient (r p ) (52) (Fig. 3C) . Overall, these data clearly show that the two cell lines respond differently to the same NP.
As a further investigation of intracellular dynamics, we measured possible exocytosis of siRNA because reports have shown that free siRNA in the cytoplasm delivered by lipid NPs can be exocytosed from cells (53) . By measuring extracellular fluorescence after administration of Cy5.5-labeled siRNA in NPs, results indicated that only a very limited (<4%) amount of siRNA was exocytosed from both cell lines up to 72 h (SI Appendix, Fig. S12 ). There was no statistical difference in the amount of exocytosed siRNA between the two cell lines. In addition, we studied the release of siRNA from NPs using an siRNA fluorescence resonance energy transfer (FRET) pair (siAF594/siAF647) (54) (SI Appendix, Fig. S13 ). When examining FRET, more RNA was measured inside of HCC4017 cells compared with HBEC30-KT, indicating greater NP disassembly. These FRET experiments, combined with the difference in lysosome colocalization (Fig. 3B) , indicate that HCC4017 endocytoses selective NPs faster and to a greater extent than normal cells, and also promotes enhanced siRNA release. Together, these experiments reveal differential cellular responses to the same NP that account for the improved cancer cell efficacy.
Cancer-Selective NPs Enabled Extended Retention in Xenograft Tumors.
We next examined the capability of selective NPs to preferentially internalize and be retained in tumors in vivo. s.c. HCC4017 tumor xenografts were formed in nude mice and injected with free Cy5.5-siRNA, nonselective Cy5.5-siRNA NPs, or selective Cy5.5-siRNA NPs. Fluorescence tracking was used to measure the decay kinetics of Cy5.5-siRNA from the tumor. Selective NPs provided extended retention of Cy5.5-siRNA (Fig. 4) inside of the tumors, which then resulted in increased efficacy (Fig. 5) .
Selective NPs stayed inside of the tumors for more than 1 wk, whereas nonselective NPs were cleared after about 6 h. Free Cy5.5-siRNA also quickly diffused away from the tumor (Fig. 4A) . Using the same imaging settings, only the selective Cy5.5-siRNA NPs showed fluorescence after 24 h. Moreover, Cy5.5-siRNA was retained in the tumor for more than 6 d. The decay of the normalized fluorescence intensity (I t /I 0 ) in these tumors quantified the retention effect of selective NPs due to degradation and diffusion of Cy5.5-siRNA in tumor tissues (Fig. 4C) . To verify the time-and polyplexdependent Cy5.5-siRNA retention, we harvested tumors and imaged tumor sections. Fluorescence imaging verified the retention observed in whole animal imaging (Fig. 4B) . To examine the effect of the polymer itself, we synthesized a Cy5.5-labeled selective polymer (PE8K-A17-0.2C6-Cy5.5). When injected into HCC4017 xenograft tumors, Cy5.5-labeled polymer NPs (no siRNA) were also retained in the tumors for >5 d (SI Appendix, Fig. S14 ). We next encapsulated Doxorubicin (Dox) into the selective NPs to examine a model chemotherapeutic drug-loaded NP, and performed similar retention studies. Again, the Dox-loaded NPs were retained for >5 d. These results clearly show that the physical chemistry of the NP provides the retention effect. The retention behavior is therefore not limited to siRNA polyplexes, which may provide future opportunities to selectively deliver other anticancer drugs.
Cancer-Selective Polyplex NPs Significantly Suppressed Tumor Growth by
Enhancing siUBB-Mediated Apoptosis. To further examine the anticancer effects of selective NPs, we performed a long-term HCC4017 , we injected PBS, nonselective siUBB NPs, selective siCtrl NPs, or selective siUBB NPs. Mice received intratumoral injections of 0.12 mg/kg siUBB on days 20, 25, and 30 (Fig. 5A) . Tumor volume measurements show that selective siUBB NPs significantly suppressed the growth of xenograft tumors (Fig. 5 A and  B) . The absence of any weight loss indicated no appreciable toxicity. Even though the nonselective NPs caused some cell death (Fig. 5 C  and D) , only the selective NPs affected tumor growth. The prolonged retention of selective NPs in tumors (Fig. 4) , combined with enhancement of delivery to tumor cells (Fig. 2 A and B) , resulted in significant growth suppression (Fig. 5 A and B) .
To verify successful delivery, we analyzed siUBB-mediated apoptosis of tumor cells. Silencing of UBB causes apoptosis through multiple pathways, including interactions with Fas-like inhibitor protein, the proapoptotic Bcl-2 family member BAX, and TRAIL signaling (27) . First, we measured caspase-3/7 activity 4-d postinjection as an indicator of programmed cell death. Quantitative caspase activity in tumor tissues show that nonselective siUBB NPs cause ∼2-fold increase in apoptosis, whereas selective siUBB NPs cause >12-fold increase in tumor cell apoptosis (Fig. 5C ). Next, we performed TUNEL assays on histological slides to visualize DNA fragmentation. Without injection, TUNEL staining shows minimal apoptosis. The apoptosis signal increased only slightly when siUBB was encapsulated in nonselective NPs. After injection of selective siUBB NPs, the area and density of the green fluorescence increased dramatically, showing that the activity of encapsulated siUBB is enhanced by the cancer-selective NPs. Accordingly, much more necrosis (shown as fewer nuclei in blue) was observed by H&E staining (Fig. 5D) , explaining why siUBB delivery inside of selective NPs arrested the growth of xenograft tumors. nonselective siLuc NPs, selective siCtrl NPs, or PBS because there was no sufficient suppression of the luciferase expression in the cancer cells. After i.v. administration of 1 mg/kg selective siLuc NPs, the luciferase signal decreased due to successful luciferase silencing in the tumor tissue (Fig. 5E ). Harvested tumors were homogenized to quantify luciferase expression on a total protein normalized level.
Results indicated that i.v. injection of the selective siLuc NPs led to ∼70% luciferase knockdown in xenograft tumors (Fig. 5F ). Finally, to further extend the translational impact of this selective NP system, we evaluated silencing ability of aerosolized NPs to an orthotopic lung cancer model. We chose a cell line (HCC1299) from our NSCLC screen that was known to colonize in the lung after i.v. administration and form orthotopic lung tumors. Selective siLuc NPs were aerosolized and delivered to mice harboring orthotopic HCC1299-Luc lung tumors. After aerosol inhalation of selective siLuc NPs, the luciferase signal in the lung tumors significantly decreased after 48 h (Fig. 5G) . Aerosol inhalation of selective NPs may be the preferred approach in the clinic. Cumulatively, these results demonstrate selective uptake and retention in tumor cells in multiple in vivo models and cell lines. This approach therefore provides a promising way to improve cancer therapy by increasing cancer selectivity.
Discussion
To minimize the side effects of conventional nontargeted chemo-and small-RNA therapeutics, we examined the hypothesis that the physiochemical properties of materials alone could endow selective delivery to specific cells. We discovered selective NPs that efficiently transfect HCC4017 lung cancer cells in vitro and in vivo, but not matched normal lung cells from the same patient. This approach has proved valuable for the discovery of small-molecule drugs and identification of genetic cancer vulnerabilities (55) . We now show that it can be used to discover drug carriers that are specific to cancer cells. This work establishes feasibility of this approach to (G) Selective siLuc NPs enable significant luciferase knockdown in HCC1299-Luc orthotopic lung tumors after administrated through aerosol inhalation. Statistical significance was determined using a two-tailed Student's t test (***, P ≤ 0.001; **, P ≤ 0.01; *, P ≤ 0.05; ns, P > 0.05).
increase on-target drug activity. It also illuminates the unappreciated reality that NP carriers exhibit cell type-dependent delivery.
In this paper, we have described an approach to enhance cancer cell delivery that does not require targeting ligand modification. This delivery carrier-based selectivity could potentially synergize with personalized medicine strategies to transform patient-centered decision making by providing customized drugs and delivery vehicles according to individual genetic profiles (56, 57) . It also highlights that fundamental cellular differences have not been fully understood in the development of delivery carriers for cancer therapy, particularly for RNA-based therapeutics. Through selectivity screening on a cancer-normal cell pair and additional NSCLC cell lines, it is clear that cells respond differently to the same NP. Most papers focus on a single cell line from a single cancer type. We demonstrate that delivery efficacy and selectivity is highly cell line-dependent, which is an unexplored phenomenon in drug delivery. It is imagined that cell-type specificity of delivery carriers in vivo could alter the efficacy of clinical gene therapies and patient outcomes. This should be carefully considered in choosing molecular targets and developing targeted delivery carriers.
Methods
Detailed materials, methods, and additional figures are provided in SI Appendix. This includes descriptions of chemical synthesis and characterization, preparation and characterization of NPs, in vitro and in vivo gene silencing, animal studies, and statistics. All experiments were approved by the Institutional Animal Care and Use Committees of The University of Texas Southwestern Medical Center and were consistent with local, state, and federal regulations as applicable.
